Sami Corwin
Stock Analyst at William Blair
(n/a)
# 4,726
Out of 4,765 analysts
9
Total ratings
n/a
Success rate
-56.18%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sami Corwin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRGX CARGO Therapeutics | Downgrades: Market Perform | n/a | $4.11 | - | 2 | Jan 30, 2025 | |
| APLT Applied Therapeutics | Downgrades: Market Perform | n/a | $0.50 | - | 1 | Dec 23, 2024 | |
| TNYA Tenaya Therapeutics | Initiates: Outperform | n/a | $0.64 | - | 1 | Jun 10, 2024 | |
| NGNE Neurogene | Initiates: Outperform | n/a | $17.24 | - | 1 | Mar 21, 2024 | |
| MESO Mesoblast | Downgrades: Market Perform | n/a | $13.31 | - | 1 | Aug 4, 2023 | |
| CRSP CRISPR Therapeutics AG | Reinstates: Outperform | $75 | $42.55 | +76.28% | 1 | May 30, 2023 | |
| LEGN Legend Biotech | Initiates: Market Perform | n/a | $38.01 | - | 1 | May 25, 2023 | |
| QURE uniQure | Initiates: Outperform | $66 | $13.24 | +398.49% | 1 | Oct 27, 2021 |
CARGO Therapeutics
Jan 30, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $4.11
Upside: -
Applied Therapeutics
Dec 23, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $0.50
Upside: -
Tenaya Therapeutics
Jun 10, 2024
Initiates: Outperform
Price Target: n/a
Current: $0.64
Upside: -
Neurogene
Mar 21, 2024
Initiates: Outperform
Price Target: n/a
Current: $17.24
Upside: -
Mesoblast
Aug 4, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $13.31
Upside: -
CRISPR Therapeutics AG
May 30, 2023
Reinstates: Outperform
Price Target: $75
Current: $42.55
Upside: +76.28%
Legend Biotech
May 25, 2023
Initiates: Market Perform
Price Target: n/a
Current: $38.01
Upside: -
uniQure
Oct 27, 2021
Initiates: Outperform
Price Target: $66
Current: $13.24
Upside: +398.49%